scispace - formally typeset
A

Angelo Branzi

Researcher at University of Bologna

Publications -  350
Citations -  17546

Angelo Branzi is an academic researcher from University of Bologna. The author has contributed to research in topics: Atrial fibrillation & Heart failure. The author has an hindex of 58, co-authored 350 publications receiving 16425 citations.

Papers
More filters
Journal ArticleDOI

Impact of high-sensitivity Troponin T on hospital admission, resources utilization, and outcomes.

TL;DR: The epidemiological, clinical and prognostic impact of introducing hs-cTnT in the everyday clinical practice of an Emergency Department did not observe overdiagnosis and overtreatment issues in presenters with suspected ACS, despite the increase in the number of patients presenting with abnormal troponin levels.
Journal ArticleDOI

Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation.

TL;DR: In patients with recent‐onset atrial fibrillation without signs of heart failure, propafenone as a single oral loading dose is effective, and it is also effective in selected elderly subjects with a favorable safety profile.
Journal ArticleDOI

High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: favorable effects of D, L-sotalol.

TL;DR: Replacement of amiodarone treatment with an alternate class III agent (D,L -sotalol or other agents, if available) can be considered as a possible option in case of high defibrillation threshold at the time of the implantation in a patient receiving continuous amiodrone treatment.
Journal ArticleDOI

Cardioverter-defibrillator oversensing due to double counting of ventricular tachycardia electrograms

TL;DR: How in some cases sensing by epicardial wires may be a solution for QRS double counting occurring with endocardial leads during ventricular tachycardia is emphasized.
Journal ArticleDOI

Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death.

TL;DR: Agents with upstream effects may also be used in high-risk patients in association with a strictly downstream intervention, such as the implantable cardioverter defibrillator, in an attempt to obtain an additive/synergetic effect.